Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Public ClinicalTrials.gov record NCT05188729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, tolerability, MTD, and objective antitumor efficacy of ascending dose strengths of VP-315 when administered intratumorally to adults with biopsy proven basal cell carcinoma (BCC). The study is expected to enroll approximately 86 subjects with a histological diagnosis of BCC in at least 1 eligible target lesion (confirmed by punch or shave biopsy).
Study identification
- NCT ID
- NCT05188729
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 92 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 1, 2022 (Actual)
- Primary completion
- Apr 15, 2024 (Actual)
- Completion
- Apr 15, 2024 (Actual)
- Last update posted
- Jun 18, 2025
2022 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Therapeutics Clinical Research | San Diego | California | 92123 | — |
| ClearlyDerm | Boca Raton | Florida | 33428 | — |
| Life Clinical Trials | Coral Springs | Florida | 33071 | — |
| Florida Center for Dermatology | Saint Augustine | Florida | 32080 | — |
| Gwinnett Dermatology | Snellville | Georgia | 30078 | — |
| Affinity Health | Oakbrook Terrace | Illinois | 60181 | — |
| DermAssociates | Rockville | Maryland | 20850 | — |
| Lawrence J Green, MD LLC | Rockville | Maryland | 20850 | — |
| ActivMed Research - Borthwick | Portsmouth | New Hampshire | 03801 | — |
| UPMC St. Margaret | Pittsburgh | Pennsylvania | 15213 | — |
| Austin Institute of Clinical Research - Dripping Springs | Dripping Springs | Texas | 78620 | — |
| Austin Institute of Clinical Research - Houston | Houston | Texas | 77056 | — |
| Austin Institute of Clinical Research - Pflugerville | Pflugerville | Texas | 78660 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05188729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2025 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05188729 live on ClinicalTrials.gov.